{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Algie post-zona : Questions médicales les plus fréquentes",
"headline": "Algie post-zona : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Algie post-zona : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-13",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Algie post-zona"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Névralgie",
"url": "https://questionsmedicales.fr/mesh/D009437",
"about": {
"@type": "MedicalCondition",
"name": "Névralgie",
"code": {
"@type": "MedicalCode",
"code": "D009437",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.592.612.664"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Algie post-zona",
"alternateName": "Neuralgia, Postherpetic",
"code": {
"@type": "MedicalCode",
"code": "D051474",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Song Cao",
"url": "https://questionsmedicales.fr/author/Song%20Cao",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Dexin Zhang",
"url": "https://questionsmedicales.fr/author/Dexin%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Jie Yuan",
"url": "https://questionsmedicales.fr/author/Jie%20Yuan",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Ying Li",
"url": "https://questionsmedicales.fr/author/Ying%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China."
}
},
{
"@type": "Person",
"name": "Yuanyuan Ding",
"url": "https://questionsmedicales.fr/author/Yuanyuan%20Ding",
"affiliation": {
"@type": "Organization",
"name": "Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Spatial Transcriptomics Identifies Cellular and Molecular Characteristics of Scleroderma Skin Lesions: Pilot Study in Juvenile Scleroderma.",
"datePublished": "2024-08-23",
"url": "https://questionsmedicales.fr/article/39273131",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25179182"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cross-sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument (LoSQI): A disease-specific patient-reported outcome measure.",
"datePublished": "2023-04-12",
"url": "https://questionsmedicales.fr/article/36950970",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jdv.19059"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Reactivation of Scleroderma After Autologous Fat Grafting.",
"datePublished": "2023-08-15",
"url": "https://questionsmedicales.fr/article/37582285",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/SCS.0000000000009614"
}
},
{
"@type": "ScholarlyArticle",
"name": "Scleroderma autoantibodies in guiding monitoring and treatment decisions.",
"datePublished": "2022-08-29",
"url": "https://questionsmedicales.fr/article/36082759",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/BOR.0000000000000904"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study.",
"datePublished": "2023-04-19",
"url": "https://questionsmedicales.fr/article/37083160",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/cca0xv"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Manifestations neurologiques",
"item": "https://questionsmedicales.fr/mesh/D009461"
},
{
"@type": "ListItem",
"position": 5,
"name": "Névralgie",
"item": "https://questionsmedicales.fr/mesh/D009437"
},
{
"@type": "ListItem",
"position": 6,
"name": "Algie post-zona",
"item": "https://questionsmedicales.fr/mesh/D051474"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Algie post-zona - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Algie post-zona",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Algie post-zona",
"description": "Comment diagnostique-t-on l'algie post-zona ?\nQuels examens peuvent être réalisés ?\nQuels symptômes indiquent une algie post-zona ?\nPeut-on confondre l'algie post-zona avec d'autres douleurs ?\nQuel rôle joue l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Algie post-zona",
"description": "Quels sont les symptômes principaux de l'algie post-zona ?\nLa douleur est-elle constante ou intermittente ?\nY a-t-il des symptômes associés ?\nComment la douleur est-elle décrite par les patients ?\nLes symptômes varient-ils d'une personne à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Algie post-zona",
"description": "Peut-on prévenir l'algie post-zona ?\nQui devrait se faire vacciner contre le zona ?\nY a-t-il des mesures à prendre après une éruption de zona ?\nLa gestion du stress aide-t-elle à prévenir l'algie ?\nLes soins de la peau sont-ils importants après le zona ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Algie post-zona",
"description": "Quels traitements sont efficaces contre l'algie post-zona ?\nLes médicaments topiques sont-ils utiles ?\nLa physiothérapie peut-elle aider ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils toujours efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Algie post-zona",
"description": "Quelles sont les complications possibles de l'algie post-zona ?\nL'algie post-zona peut-elle affecter la qualité de vie ?\nY a-t-il un risque de dépression avec l'algie post-zona ?\nLes douleurs peuvent-elles s'aggraver avec le temps ?\nDes infections peuvent-elles survenir après le zona ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Algie post-zona",
"description": "Quels sont les facteurs de risque de l'algie post-zona ?\nLe stress est-il un facteur de risque ?\nLes personnes atteintes de maladies chroniques sont-elles à risque ?\nLes femmes sont-elles plus à risque que les hommes ?\nL'immunosuppression augmente-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D051474?mesh_terms=Scleroderma,+Localized&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on l'algie post-zona ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical et l'examen physique, sans tests spécifiques."
}
},
{
"@type": "Question",
"name": "Quels examens peuvent être réalisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie comme l'IRM peuvent être utilisés pour exclure d'autres causes de douleur."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une algie post-zona ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une douleur intense, brûlante ou lancinante dans la zone de l'éruption cutanée est typique."
}
},
{
"@type": "Question",
"name": "Peut-on confondre l'algie post-zona avec d'autres douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres douleurs neuropathiques ou musculo-squelettiques."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique d'une infection par le virus varicelle-zona est crucial pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux de l'algie post-zona ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur intense, hypersensibilité et parfois démangeaisons."
}
},
{
"@type": "Question",
"name": "La douleur est-elle constante ou intermittente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur peut être constante ou survenir par épisodes, souvent aggravée par le toucher."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, l'anxiété et des troubles du sommeil peuvent être présents."
}
},
{
"@type": "Question",
"name": "Comment la douleur est-elle décrite par les patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients décrivent souvent la douleur comme brûlante, lancinante ou en coup de poignard."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la durée des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'algie post-zona ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination contre le zona peut réduire le risque de développer l'algie post-zona."
}
},
{
"@type": "Question",
"name": "Qui devrait se faire vacciner contre le zona ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les adultes de 50 ans et plus sont recommandés pour recevoir le vaccin contre le zona."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures à prendre après une éruption de zona ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de consulter un médecin rapidement après une éruption pour un traitement précoce."
}
},
{
"@type": "Question",
"name": "La gestion du stress aide-t-elle à prévenir l'algie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress peut aider à réduire le risque de douleurs chroniques après le zona."
}
},
{
"@type": "Question",
"name": "Les soins de la peau sont-ils importants après le zona ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, maintenir la peau propre et hydratée peut aider à prévenir les complications cutanées."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre l'algie post-zona ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des analgésiques, des anticonvulsivants et des antidépresseurs."
}
},
{
"@type": "Question",
"name": "Les médicaments topiques sont-ils utiles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des crèmes anesthésiques peuvent soulager la douleur localement dans certains cas."
}
},
{
"@type": "Question",
"name": "La physiothérapie peut-elle aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La physiothérapie peut aider à gérer la douleur et améliorer la fonction dans certains cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme la thérapie cognitivo-comportementale peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils toujours efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements varie, et certains patients peuvent ne pas répondre aux thérapies."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'algie post-zona ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des douleurs chroniques, des troubles du sommeil et de l'anxiété."
}
},
{
"@type": "Question",
"name": "L'algie post-zona peut-elle affecter la qualité de vie ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur chronique peut significativement impacter la qualité de vie et le bien-être."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de dépression avec l'algie post-zona ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur chronique peut augmenter le risque de dépression chez les patients."
}
},
{
"@type": "Question",
"name": "Les douleurs peuvent-elles s'aggraver avec le temps ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas, la douleur peut devenir plus intense et persistante avec le temps."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles survenir après le zona ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections cutanées peuvent survenir si la peau est lésée pendant l'éruption."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'algie post-zona ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, un système immunitaire affaibli et des antécédents de zona."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affaiblir le système immunitaire et augmenter le risque d'algie post-zona."
}
},
{
"@type": "Question",
"name": "Les personnes atteintes de maladies chroniques sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies chroniques peuvent augmenter le risque de développer l'algie post-zona."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque que les hommes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que les femmes peuvent être légèrement plus à risque que les hommes."
}
},
{
"@type": "Question",
"name": "L'immunosuppression augmente-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunosupprimées ont un risque accru de développer l'algie post-zona."
}
}
]
}
]
}
Juvenile localized and systemic scleroderma are rare autoimmune diseases which cause significant disability and morbidity in children. The mechanisms driving juvenile scleroderma remain unclear, neces...
The Localized Scleroderma Quality of Life Instrument (LoSQI) is a disease-specific patient-reported outcome (PRO) measure designed for children and adolescents with localized scleroderma (LS; morphea)...
The purpose of this study was to evaluate the psychometric properties of the LoSQI in a clinical setting....
Cross-sectional data from four specialized clinics in the US and Canada were included in the analysis. Evaluation included reliability of scores, internal structure of the survey, evidence of converge...
One hundred and ten patients with LS (age: 8-20 years) completed the LoSQI. Both exploratory and confirmatory factor analysis supported the use of two sub-scores: Pain and Physical Functioning, and Bo...
This study did not evaluate longitudinal validity or responsiveness of scores....
Results from a representative sample of children and adolescents with LS continue to support the validity of the LoSQI when used in a clinical setting. Future work to evaluate the responsiveness is on...
Patients with localized scleroderma (LS) often have to seek plastic surgery to improve facial esthetic impairment....
The authors reported a case of the reactivation of LS after autologous fat grafting (AFG)....
A man presented with facial atrophy and skin fibrosis on the cheek with a history of LS. The disease had remained stable for 9 years and he was suggested to stop oral medication. With irreversible est...
Six months after the last AFG, the patient found new lesions occur on the lateral forehead. The patient was later diagnosed with reactivation of LS....
The understanding of the surgical risk and perioperative management for patients with LS needs more research....
One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the dia...
There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows...
ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future res...
People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in pe...
The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analys...
Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by...
People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering t...
Systemic sclerosis (SSc) represents extremely rare disease with majority of data coming from adults. Studies comparing juvenile- (jSSc) and adult-onset (aSSc) patients are limited. We aimed to compare...
A retrospective study among pediatric and adult Scl patients has been performed. Demographic characteristics, clinical features, autoantibody profiles, and treatment data were retrieved from the datab...
A total of 158 adults and 58 juvenile Scl patients were identified. The mean age at the disease onset was 37±14.7 vs. 8.8 ± 4.1 years, mean age at diagnosis 42±15.2 vs. 10.4 ± 3.8 years and mean follo...
Juvenile and adult-onset Scl represent rarely seen conditions with different clinical phenotypes. Pediatric patients with LS are more commonly seen by pediatric rheumatologists, in contrary to adults....
We investigated the ability of a panel of immune-related cytokines and chemokines to predict the disease activity state in localized scleroderma (LS) subjects followed longitudinally. A total of 194 s...
Systemic sclerosis (SSc) is characterized by the presence of SSc-specific or SSc-associated antibodies (SSc-Abs): anti-topoisomerase I (ATA), anti-centromere (ACA), anti-RNA polymerase III (ARA), anti...
Erectile dysfunction (ED) has been reported among patients with systemic sclerosis (SSc) and primarily limited cutaneous SSc in Caucasians. While there is no data on ED among Thais in whom the diffuse...
We aimed to estimate the prevalence of ED among Thais with SSc, evaluate its severity, and determine the associated factors....
We did a cross-sectional study among adult Thai male SSc patients. All eligible patients: a) completed the IIEF-15 questionnaire by themselves; b) underwent a genital examination by an experienced uro...
A total of 60 male SSc patients were included. The respective mean age and median disease duration was 54.8±7.2 years and 3.1 years (IQR 1.2-7.2). The definition of ED was fulfilled in 53 cases for a ...
ED is a common problem in men with SSc and is mainly categorized as severe. The severity of SSc might increase the risk of developing ED. We found phimosis was a common genital abnormality co-occurrin...
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) with a mortality of 20% at 6 months. Once the leading cause of mortality in scleroderma (SSc), it remains ...